Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Low-level Cxcr4-haploinsufficient HSC engraftment is sufficient to correct leukopenia in WHIM syndrome mice
Ji-Liang Gao, Albert Owusu-Ansah, Andrea Paun, Kimberly Beacht, Erin Yim, Marie Siwicki, Alexander Yang, Qian Liu, David H. McDermott, Philip M. Murphy
Ji-Liang Gao, Albert Owusu-Ansah, Andrea Paun, Kimberly Beacht, Erin Yim, Marie Siwicki, Alexander Yang, Qian Liu, David H. McDermott, Philip M. Murphy
View: Text | PDF
Research Article Immunology Stem cells

Low-level Cxcr4-haploinsufficient HSC engraftment is sufficient to correct leukopenia in WHIM syndrome mice

  • Text
  • PDF
Abstract

Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome immunodeficiency is caused by autosomal dominant gain-of-function mutations in chemokine receptor CXCR4. Patient WHIM-09 was spontaneously cured by chromothriptic deletion of 1 copy of 164 genes, including the CXCR4WHIM allele, presumably in a single hematopoietic stem cell (HSC) that repopulated HSCs and the myeloid lineage. Testing the specific contribution of CXCR4 hemizygosity to her cure, we previously demonstrated enhanced engraftment of Cxcr4+/o HSCs after transplantation in WHIM (Cxcr4+/w) model mice, but the potency was not quantitated. We now report graded-dose competitive transplantation experiments using lethally irradiated Cxcr4+/+ recipients in which mixed BM cells containing approximately 5 Cxcr4+/o HSCs and a 100-fold excess of Cxcr4+/w HSCs achieved durable 50% Cxcr4+/o myeloid and B cell chimerism in blood and approximately 20% Cxcr4+/o HSC chimerism in BM. In Cxcr4+/o/Cxcr4+/w parabiotic mice, we observed 80%–100% Cxcr4+/o myeloid and lymphoid chimerism in the blood and 15% Cxcr4+/o HSC chimerism in BM from the Cxcr4+/w parabiont, which was durable after separation from the Cxcr4+/o parabiont. Thus, CXCR4 haploinsufficiency likely significantly contributed to the selective repopulation of HSCs and the myeloid lineage from a single chromothriptic HSC in WHIM-09. Moreover, the results suggest that WHIM allele silencing of patient HSCs is a viable gene therapy strategy.

Authors

Ji-Liang Gao, Albert Owusu-Ansah, Andrea Paun, Kimberly Beacht, Erin Yim, Marie Siwicki, Alexander Yang, Qian Liu, David H. McDermott, Philip M. Murphy

×

Figure 2

Durable low-level Cxcr4+/o HSC chimerism in BM supports a high level of blood leukocyte chimerism in Cxcr4+/w mice.

Options: View larger image (or click on image) Download as PowerPoint
Durable low-level Cxcr4+/o HSC chimerism in BM supports a high level of ...
(A) Experimental design. To track leukocytes, each parabiont has a different congenic CD45 background from its partner (CD45.2 or CD45.1/.2). +/o, Cxcr4+/o; +/w, Cxcr4+/w; +/+, Cxcr4+/+. (B–D) Mature leukocyte chimerism analysis in blood and BM. Leukocyte subsets are defined by immunophenotype at the top of each column of panels. Symbols for the genotypes of each parabiont are defined at the right. Top row of graphs in each panel: data from Cxcr4+/+ /Cxcr4+/+ parabiosis; bottom row of graphs in each panel: data from Cxcr4+/o /Cxcr4+/w parabiosis. (B) Time course in blood. Vertical dashed lines indicate the time when the parabiotic mice were separated. (C and D) BM chimerism 5 months after parabiotic surgery, the time of separation of the parabionts (C), or 5 months after separation of the parabionts (D). Blood chimerism at the same 2 time points is reproduced in C and D from B for direct comparison. (E) HSC and HPC analysis in BM. The time of BM analysis is indicated at the top of each panel, and the symbols for each parabiont genotype are defined at the top left within each panel. LSK, lineage-Sca-1+c-Kit+ BM cells; LT-and ST-HSC, long-term and short-term hematopoietic stem cells; MPP, multipotential progenitor cells; CLP, common lymphoid precursor cells. (B–E) Data are the summary of all parabiotic pairs created and are presented as the percentage (mean ± SEM) of partner cells in each parabiont for each subset. In the connected phase, a total of 5 Cxcr4+/o/Cxcr4+/w pairs and 4 Cxcr4+/+/Cxcr4+/+ pairs were studied. Of these, 3 pairs were terminated in each group for BM analysis at the end of the connected phase, leaving 2 Cxcr4+/o/Cxcr4+/w pairs and 1 Cxcr4+/+/Cxcr4+/+ pair for study in the separated phase. Cxcr4+/o/Cxcr4+/w data are combined from parabiotic pairs that were differentially marked with CD45 isoforms both possible ways (i.e., Cxcr4+/o CD45.1/.2: Cxcr4+/w CD45.2 and Cxcr4+/o CD45.2: Cxcr4+/w CD45.1/.2), since the results were the same, indicating no effect of CD45 polymorphism. *P < 0.05; **P < 0.01; ***P < 0.005. Single comparisons, Student’s t test; multiple comparisons, 2-way ANOVA.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts